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INTRODUCTION 
This paper attempts a brief discussion of the rabbit 
niodel of bacterial meningitis originally described by 
Dacey and Sande in 1974 111. It is no overstatement to 
say that this model is one of the most widely used 
infectious dlsease models and has substantially contri- 
buted to our understanlng of many aspects of bacterial 
meningitis, including, but not: limited to, antibiotic 
therapy. A more detailed discussion of the benefits and 
limitations of the model and its technical aspects has 
recently been published 121. 
A review of the basic technical aspects of the 
model leads one to appreciate both the strengths and 
limitations of the model. In brief, juvenile rabbits are 
anesthetized and then infected by direct injection of the 
bacterial inoculum into the cerebrospinal fluid (CSF) 
in the cisterna magna. The disease then develops over 
12-24 h. The size of the animal and the relative ease of 
access to the CSF allow for sequential sampling of 
CSF of up to -0.3 mL per sample. Venous and arterial 
access can also be easily established in the rabbit, thus 
allowing one to infuse drugs, collect blood specimens, 
and monitor arterial blood pressure, blood gas or other 
physiologic parameters. These basic characteristics make 
the model almost ideal for the study of aspects related 
to the therapy of meningitis. Antibiotics can be infused 
intravenously, repeated CSF saniples and blood samples 
allow for detailed pharmacokinetic evaluations, and 
the sequential determination of bacterial titers in the 
CSF provides a precise assessnient of the bactericidal 
effect of therapy unparalleled by most other infection 
models. Consequently, numerous studies have addressed 
the kinetics of CSF penetration of antibiotics in the 
presence and absence of CSF inflammation, identified 
host and drug factors affecting access of antibiotics to 
the CSF, and characterized the CSF bactericidal activity 
of antibiotics (for a brief review, see Tauber and Sande 
[3]) .  In addition to these therapeutic studies, several 
groups have utilized the advantages of the model to 
study molecular aspects of CSF inflammation and the 
pathophysiology of meningitis (recently reviewed by 
Pfister et a1 141). 
The most significant disadvantage of the model is 
also readily apparent from the technical description. 
The mode of infection, which relies on the injection 
of large numbers of organisms directly into the CSF, 
bypasses the early events (bacteremia, transmigration 
of low numbers of organisms across the blood-brain 
barrier into the central nervous system) that typically 
lead to meningitis in humans. Thus, the early events of 
the pathogenesis of meningitis can be studied only to a 
very limited extent in the rabbit model. Furthermore, 
in the rabbit the disease does not lead to widespread 
neuronal injury, as can be observed in other models [5], 
and the rabbit model is therefore not suited for studies 
of neuronal injury. 
TECHNICAL ASPECTS 
Experimental work with animals poses important 
ethical questions, and adherence to internationally 
accepted standards of animal welfare and protection in 
the performance of such work is vital. Accordingly, 
review and approval of planned experiments by an 
appropriate institutional committee for animal care 
must be obtained before any work can be started. 
Anesthesia 
It is important that all experimental procedures, 
including access to the cisterna magna, be performed 
in anesthetized animals. Proper anesthesia that makes 
animals completely non-responsive to noxious stimuli, 
while having a low anesthesia-related mortality, is a key 
requirement for successful experiments in this model. 
Inadequate anesthesia will lead to reflex movements of 
the rabbit during tapping, with associated bleeding and 
often fatal injury to the spinal cord. We use as short- 
lasting anesthesia (for the attachment of the helmet, 
puncture of the cisterna magna, insertion of vascular 
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catheters) either pentobarbital (20-45 mg/kg IV), or an 
intraniuscular mixture of ketamine (35-50 nig/kg) and 
sylazine (2-5 mg/kg), often combined with azepro- 
niazine (0.5-1 nig/kg). The intramuscular mixture has 
the advantage of a very low mortality, but induction 
of anestheTia is slower than with intravenous pento- 
barbital. I n  addition, we apply lidocaine (1% SC) 
\Thenever we perform skin incisions. For long-lasting, 
noti-survival anesthesia (the final phase of the experi- 
ment which ends with euthanasia) we use intravenous 
urethane, approximately 2 g/kg, given in slow incre- 
ments dosed to effect. For euthanasia, we administer an 
intravenous overdose of pentobarbital (200 nig/kg). 
CSF access 
In the original description of the model, CSF access is 
secured by the use of a special franie designed to 
introduce into the cisterna magna a 25-gauge spinal 
needle [l]. With four steel screws, a dental acrylic cap 
containing a turnbuckle is molded to the exposed skull 
of the rabbit, and the turnbuckle is then used to secure 
the head of the rabbit in a firm position in the frame. 
A geared electrode introducer then allows the cautious 
Jdvancement of a spinal needle into the cisterna niagna 
by penetrating the shaved skin just below the rabbit’s 
occiput. The needle can be secured in this position for 
hours at  a time, allowing virtually continuous access to 
the CSF space and repeated sampling of fluid. While 
the alniost permanent access to the CSF space may be 
needed for specific experimental investigations, the 
technical effort involved is considerable. We have 
therefore modified the model to access the cisterna 
niagna without the frame or the dental acrylic cap by 
using a 25-gauge butterfly needle for direct puncture 
of the structure. The anesthetized animal is placed on 
its side on 3 flat surface, the neck i s  gently flexed, and 
the needle is inserted by hand just below the occiput. 
In most cases, freely flowing clear CSF will readily 
appear in the tube and can then be gently aspirated with 
a syringe. The same approach is also used to inject 
the inoculuni. After each tap. the butterfly needle is 
removed, and a new needle is inserted for the next tap. 
Infection 
A wide range of meningeal pathogens can arid has 
been used in this model ( e . ~ .  StrtpfomCctij yrieuinoi7iar, 
Unoriopliilus ir!flirenzue, group B streptococci, Listeria 
iqioriocytopries, Eschevichia c-oli, Kltbsiella spp., Proteus spp., 
P5cirdoiqioiias ucngieinorn). I t  is best to select a clinical 
isolate of the organism to be studied. Animals can be 
infected with bacterial suspensions prepared from either 
frozen aliquots or logarithmic-phase cultures washed 
and resuspended i n  saline or phosphate-buffered saline 
(PBS). Almost invariably, organisms will become niore 
virulent if they are repeatedly passaged through animals 
(i.e. infect an animal intracisternally, culture organism 
from CSF, infect next animal, culture organism, etc.). 
For each organism, the optimal inoculum size (typically 
somewhere between 10s and 10’ CFU in 0.3 niL), and 
the optimal duration between infection and initiation 
of therapy (-12 h to 18 h) must be established. The 
goal is to produce a well-established infection with 
high CSF bacterial titers, without incurring significant 
mortality (< 10% of animals should die before initiation 
of therapy). An important practice that can help to 
reduce mortality is to adequately hydrate animals with 
subcutaneous saline after they have been infected, since 
they will stop drinking as a result of the developing 
disease. 
Therapy and endpoints 
Studies designed to evaluate the efficacy ofan antibiotic 
iii treating meningitis should be started when the 
disease is fully developed, i.e. the bacteria have reached 
high CSF titers (> lo5  CFU/niL) and there is CSF 
inflaniniation present with a granulocytic pleocytosis 
and increased CSF protein and lactate concentration\. 
Antibiotics can be administered as continuous intra- 
venous infusion or as bolus injections, the former 
allowing the establishment of steady-state serum coil- 
centrations during therapy (particularly when the 
infusion is started with a bolus equivalent to J 1-2-h 
dose of the continuous infusion) [6]. In order to obtain 
a reliable assessinent of the bactericidal activity of a 
particular drug, treatment should be extended for a t  
least 5-7 11. Before and a t  regular intervals during 
therapy (every 1-2 h), CSF bacterial titers are deter- 
mined. We plate 50 pL of undiluted CSF (resulting 
in a level of detection of 20 CFU/niL) and 10-fold 
dilutions in saline on solid media in order to obtain 
quantitative cultures. Whenever possible, attempts 
should be made to avoid a carryover effect in situations 
where high concentrations of antibiotics are expected 
to be present in CSF. With p-lactani antibiotics, this is 
best achieved by adding ‘I p-lactaniase to  the CSF 
sample. The bactericidal rate in CSF can be calculated 
as Alogl,, CFU/niL per hour. Relatively detailed 
pharmacokinetic assessnients can be performed by 
obtaining ~iniultaneous CSF and serum drug levels 
during the course of therapy [6]. 
References 
1. I lacrv  KG. Sande MA. E&ct of probenecid on cerebrospinal 
fluid concentration? of penicillin a n d  crphalosporin derivatiw\. 
Antimicrob Agents Chci1iotht.i- 1074. 6 .  437-4 1 
2. Tiuber MC;. Zwahlen A. Aiiiiiial models ofmrmtigitir. In Clark 
VL, 13avod PM, cds. Methods in cnzyniology. S m  llicgo: 
Acadrimc Press, 1994. 93-lOh 
N o t e s  a n d  C o m m e n t s  559 
3. Tauber MG, Sande MA. Pharmacodynamics of antibiotics in 
experimental bacterial meningitis--two sides to rapid bacterial 
killing in the cerebrospinal fluid. Scand J Infect Dis 1991; 
74(suppl): 173-8. 
4. Pfister HW, Fontana A, Tauber MG, Tomasz A, Scheld WM. 
Mechanisms of brain injury in bacterial meningitis: Workshop 
summary. Clin Infect Dis 1994; 19. 463-79. 
5. Kim YS, Sheldon RA, Elliot BR, Liu Q, Ferriero IIM, Tauber 
MG. Brain damage in neonatal meningitis caused by group B 
meptococci in rats. J Neuropathol Exp Neurol 1995; 54: 531-9. 
6. Nau R, Schmidt T, Tauber MG. Quinolone antibiotics in 
experimental pneumococcal meningitis in rabbits. Antirnicrob 
Agents Cheniother 1995; 3 9  593-7. 
Animal models of co-infection 
Clin Microbiol Infect 1998; 4: 55'3-562 
Francis Derouin I*, Claire Ldcroix *, Monique Brun-Pascaud ', FranGoise Chau ', 
Martine Sine$, Caroline Maslo and Pierre-Marie Girard3 
Laboratoire de Parasitologie-Mycologie, H6pital Saint-Louis, 1, Avenue Claude Vellefaux, 
75475, Paris Cedex 10, France; 'INSERM Unit6 13, H6pital Bichat-Claude Bernard, and 
3Service des Maladies Infectieuses, Hbpital Rothschild, Paris, France 
*Tel: +33 1 42 49 95 01 Fax: +33 1 42 49 48 03 E-mail: paracord@wanado.Fr 
INTRODUCTION 
During their lives, animals arid humans are usually 
co-infected with various micro-organisms, some of 
which remain latent for years. Several lines of evidence 
suggest that various interactions exist between the 
immune responses generated by different pathogens 
and that the pathogenesis of one infection may be 
markedly influenced by concurrent infection by another 
microorganism. 
Indeed, in vitro models have shown evidence of 
such interactions at a cellular level, especially for 
pathogens co-infecting the same cell compartment. 
However, animal models are needed the better to 
understand the process of host defense in cases of 
multiple infections, and to characterize the possible 
stimulating or wasting effects of the host responses 
against one microbial agent on the resistance or 
susceptibility to another. These models are also useful 
to examine the effect of therapy against one pathogen 
on the course of infection of associated pathogens, and 
assess the efficacy of antimicrobial agents for multiple 
therapy or prophylaxis. 
MODELS OF CO-INFECTION FOR PATHOGENIC 
STUDIES 
The interactions between the pathogens and the host 
are complex, and may be either direct, as seen when 
both microorganisms are intracellular, and/or indirect, 
through the inflammatory or immune responses gener- 
ated by each infectious agent. 
Several experiments have revealed the beneficial 
effect of co-infections: in various niodels of concurrent 
bacterial, protozoal and fungal infections, it has been 
shown that an infection by one pathogen could result 
in protection against a second microorganism. In some 
cases, this protection could be related to cross-reactivity 
and protective immunity between closely related 
microorganisms, raising the possibility of hetero- 
immunization or possible vaccination with non- 
virulent organisms. In other cases, the protection could 
be obtained with unrelated organisms, providing 
evidence of the role of non-specific immunity. For 
instance, this was shown in models of Cryptococcus 
neojorvnans infection in which partial resistance could be 
conferred by concurrent infection with Toxoplasma 
gondii [1] or Listeria [2]. We also noticed such 
interaction in a mouse model of concurrent chronic 
toxoplasma and Mycobacteriuvn avinm (MAI) infection 
in which co-infected mice presented with less clinical 
symptoms of illness than those infected by each agent 
alone, despite the fact that the kinetics of parasite 
burdens in brain and lungs and bacterial loads in lungs 
and spleen showed no difference between singly or 
dually infected mice. This was especially noted within 
